174 related articles for article (PubMed ID: 37377225)
1. Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression.
Sarwar S; Tome ME; Billheimer D; Spier C; Smith CL; Persky D; Schmelz M
Histol Histopathol; 2024 Mar; 39(3):319-331. PubMed ID: 37377225
[TBL] [Abstract][Full Text] [Related]
2. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
Kaimi Y; Takahashi Y; Taniguchi H; Ochi T; Makino H; Makita S; Iwaki N; Fukuhara S; Munakata W; Ogawa C; Izutsu K; Maeshima AM
Virchows Arch; 2024 Mar; 484(3):465-473. PubMed ID: 38349387
[TBL] [Abstract][Full Text] [Related]
3. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.
Seliem RM; Ferry JA; Hasserjian RP; Harris NL; Zukerberg LR
J Hematop; 2011 Sep; 4(3):175. PubMed ID: 32288859
[TBL] [Abstract][Full Text] [Related]
4. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
[TBL] [Abstract][Full Text] [Related]
6. GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities.
Kezlarian B; Alhyari M; Venkataraman G; Karner K; Inamdar KV; Menon MP
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):180-184. PubMed ID: 28877074
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Nikolaenko L; Nademanee A
Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
[TBL] [Abstract][Full Text] [Related]
9. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
10. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
11. EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults.
Huppmann AR; Nicolae A; Slack GW; Pittaluga S; Davies-Hill T; Ferry JA; Harris NL; Jaffe ES; Hasserjian RP
Am J Surg Pathol; 2014 Mar; 38(3):316-24. PubMed ID: 24525501
[TBL] [Abstract][Full Text] [Related]
12. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
[TBL] [Abstract][Full Text] [Related]
13. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R
Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003
[TBL] [Abstract][Full Text] [Related]
14. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Moore EM; Swerdlow SH; Gibson SE
Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
[TBL] [Abstract][Full Text] [Related]
15. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.
Xiao Q; Shen N; Hedvat CV; Moskowitz CH; Sussman LK; Filippa DA; Zelenetz AD; Houldsworth J; Chaganti RS; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):211-5. PubMed ID: 15551733
[TBL] [Abstract][Full Text] [Related]
16. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
Maruyama D
Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
[TBL] [Abstract][Full Text] [Related]
17. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.
Eberle FC; Song JY; Xi L; Raffeld M; Harris NL; Wilson WH; Pittaluga S; Jaffe ES
Am J Surg Pathol; 2012 May; 36(5):716-25. PubMed ID: 22367293
[TBL] [Abstract][Full Text] [Related]
18. Nodular Lymphocyte-predominant Hodgkin Lymphoma With Nodular Sclerosis: An Underrecognized Feature Associated With Pattern D.
El Hussein S; Wang X; Fang H; Jelloul FZ; Wang W; Loghavi S; Vega F; Miranda RN; Muzzafar T; Manning JT; Khoury JD; Burack WR; Evans AG; Medeiros LJ
Am J Surg Pathol; 2022 Sep; 46(9):1291-1297. PubMed ID: 35575765
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus infection patterns in nodular lymphocyte-predominant Hodgkin lymphoma.
Gerhard-Hartmann E; Jöhrens K; Schinagl LM; Zamó A; Rosenwald A; Anagnostopoulos I; Rosenfeldt M
Histopathology; 2022 Jun; 80(7):1071-1080. PubMed ID: 35322462
[TBL] [Abstract][Full Text] [Related]
20. Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non-Hodgkin lymphoma.
Debliquis A; Baseggio L; Bouyer S; Guy J; Garnache-Ottou F; Genevieve F; Mayeur-Rousse C; Letestu R; Chapuis N; Harrivel V; Bennani H; Lachot S; Loosveld M; Nicolino-Brunet C; Pérès M; Roussel M; Veyrat-Masson R; Jacob MC; Drenou B
Cytometry B Clin Cytom; 2021 Jul; 100(4):488-496. PubMed ID: 32803917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
